A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
- Conditions
- Moderate to Severe Ulcerative Colitis
- Interventions
- Drug: Induction- PF-06480605 450 mg SC Q4WOther: Induction- Placebo SC Q4WDrug: Induction- PF-06480605 50 mg SC Q4WDrug: Induction- PF-06480605 150 mg SC Q4WDrug: Chronic- PF-06480605 50 mg SC Q4WDrug: Chronic- PF-06480605 150 mg SC Q4WDrug: Chronic- PF-06480605 450 mg SC Q4W
- Registration Number
- NCT04090411
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo. After induction is complete all subjects will receive active therapy for 40 weeks, followed by a 12 week follow up period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 246
-
A diagnosis of UC for ≥3 months.
-
Participants with moderate to severe active UC as defined by a Total Mayo Score of
≥6, and an endoscopic subscore of ≥2.
-
Active disease beyond the rectum (>15 cm of active disease from the anal verge at the screening endoscopy).
-
Must have failed or been intolerant to at least one of the following class of medications: steroids, immunosuppressants, anti-TNFs, anti-integrin inhibitors, anti- IL-12/23 inhibitors, or JAK inhibitors.
- Participants with a diagnosis of ischemic colitis, infectious colitis, radiation colitis, microscopic colitis, indeterminate colitis, or findings suggestive of Crohn's disease (eg, skip lesions, fistulae/perianal disease, non-necrotizing granulomas, etc.).
- Participants with an imminent need for surgery or with elective surgery scheduled to occur during the study
- Chest Radiograph showing abnormalities: The study will accept a Chest x-ray or computed tomography scan of the chest examination performed up to 12 weeks prior to screening if available.
- 12-lead electrocardiogram (ECG) that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results
- Infected with tuberculosis, (TB): Any evidence of untreated latent or active TB infection.
- Infected with human immunodeficiency virus, (HIV), Hepatitis B or C viruses
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 9 Induction- PF-06480605 450 mg SC Q4W Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W Cohort 1 Induction- Placebo SC Q4W Induction - Placebo SC Q4W, (sub-cutaneous every 4 weeks) Chronic- PF-06480605 50 mg SC Q4W Cohort 1 Chronic- PF-06480605 50 mg SC Q4W Induction - Placebo SC Q4W, (sub-cutaneous every 4 weeks) Chronic- PF-06480605 50 mg SC Q4W Cohort 2 Induction- Placebo SC Q4W Induction - Placebo SC Q4W, Chronic- PF-06480605 150 mg SC Q4W Cohort 2 Chronic- PF-06480605 150 mg SC Q4W Induction - Placebo SC Q4W, Chronic- PF-06480605 150 mg SC Q4W Cohort 3 Induction- Placebo SC Q4W Induction - Placebo SC Q4W, Chronic- PF-06480605 450 mg SC Q4W Cohort 3 Chronic- PF-06480605 450 mg SC Q4W Induction - Placebo SC Q4W, Chronic- PF-06480605 450 mg SC Q4W Cohort 4 Induction- PF-06480605 50 mg SC Q4W Induction- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W Cohort 4 Chronic- PF-06480605 50 mg SC Q4W Induction- PF-06480605 50 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W Cohort 5 Induction- PF-06480605 150 mg SC Q4W Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W Cohort 5 Chronic- PF-06480605 50 mg SC Q4W Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W Cohort 6 Induction- PF-06480605 150 mg SC Q4W Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W Cohort 6 Chronic- PF-06480605 150 mg SC Q4W Induction- PF-06480605 150 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W Cohort 7 Induction- PF-06480605 450 mg SC Q4W Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W Cohort 7 Chronic- PF-06480605 50 mg SC Q4W Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 50 mg SC Q4W Cohort 8 Induction- PF-06480605 450 mg SC Q4W Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W Cohort 8 Chronic- PF-06480605 150 mg SC Q4W Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 150 mg SC Q4W Cohort 9 Chronic- PF-06480605 450 mg SC Q4W Induction- PF-06480605 450 mg SC Q4W, Chronic- PF-06480605 450 mg SC Q4W
- Primary Outcome Measures
Name Time Method Proportion of participants achieving clinical remission (defined as a Total Mayo Score ≤2, with no individual subscore >1) at Week 14. Safety and tolerability will also be assessed week 0-14 Incidence of serious adverse events (SAEs) during the induction period. week 0-14 Incidence of clinically significant abnormalities in vital signs, electrocaridograms, (ECGs) and laboratory values during the induction period. week 0-14 Incidence of AEs or SAEs leading to discontinuation during the chronic therapy period. Weeks 14-64 Incidence and severity of treatment emergent adverse events (TEAEs) during the induction period. week 0-14 Incidence and severity of treatment emergent adverse events (TEAEs) during the chronic therapy period. Weeks 14-64 Incidence of AEs or SAEs leading to discontinuation during the induction period. week 0-14 Incidence of serious adverse events (SAEs) during the chronic therapy period. Weeks 14-64 Incidence of clinically significant abnormalities in vital signs, ECGs and laboratory values during the chronic therapy period. Weeks 14-64
- Secondary Outcome Measures
Name Time Method Proportion of participants achieving remission Food and Drug Administration, ((FDA) definition 1 - defined as endoscopic subscore = 0 or 1, stool frequency subscore = 0, and rectal bleeding subscore = 0) at Week 14. week 0-14 Proportion of participants achieving endoscopic improvement (defined as endoscopic subscore = 0 or 1) at Week 14. week 0-14 Proportion of participants achieving endoscopic remission (defined as endoscopic subscore = 0) at Week 14. week 0-14 Change from baseline in serum sTL1A during the induction period through Week 14. week 0-14 Proportion of participants achieving remission (FDA definition 2 - defined as endoscopic subscore = 0 or 1, ≥1 point decrease from baseline to achieve a stool frequency subscore = 0 or 1, and rectal bleeding subscore = 0) at Week 14. week 0-14 PF 06480605 trough concentrations during the induction period through Week 14. week 0-14 Change from baseline in fecal calprotectin during the induction period through Week 14. week 0-14 Change from baseline in hsCRP during the induction period through Week 14. week 0-14 Proportion of participants achieving sustained remission-FDA definition 1 (ie, remission-FDA definition 1 at both Week 14 and Week 56). Weeks 14-56 Proportion of participants achieving sustained remission-FDA definition 2 (ie, remission-FDA definition 2 at both Week 14 and Week 56). Weeks 14-56 Incidence of development of anti drug antibodies (ADAs) and neutralizing antibodies (NAbs) during the induction period through Week 14. week 0-14 Proportion of participants achieving clinical remission (defined as a Total Mayo Score >/= to 2, with no individual subscore >1) at Week 56. Weeks 14-56 Proportion of participants achieving sustained clinical remission (ie, clinical remission at both Week 14 and Week 56). Weeks 14-56 Proportion of participants achieving remission (FDA definition 1 - defined as endoscopic subscore = 0 or 1, stool frequency subscore = 0, and rectal bleeding subscore = 0) at Week 56. Weeks 14-56 Proportion of participants achieving endoscopic improvement (defined as endoscopic subscore = 0 or 1) at Week 56. Weeks 14-56 Proportion of participants achieving sustained endoscopic improvement (ie, endoscopic improvement at both Week 14 and Week 56). Weeks 14-56 Proportion of participants achieving endoscopic remission (defined as endoscopic sub-score = 0) at Week 56. Weeks 14-56 PF-06480605 concentration from Week 14 through the End of Study Visit. Weeks 14-64 Change from week 14 in serum sTL1A during the chronic therapy period through the End of Study Visit. Weeks 14-64 Proportion of participants achieving sustained endoscopic remission (ie, endoscopic remission at both Week 14 and Week 56). Weeks 14-56 Change from baseline through the End of the Study Visit in hsCRP. Weeks 14-64 Change from Week 14 in fecal calprotectin during the chronic therapy period through the End of Study Visit Weeks 14-64 Change from Week 14 in hsCRP during the chronic therapy period through the End of Study Visit. Weeks 14-64 Change from baseline through the End of the Study Visit in fecal calprotectin weeks 14-64 Incidence of development of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) from Week 14 through the End of Study Visit. Weeks 14-64 Change from baseline through the End of Study Visit in serum sTL1A. Weeks 14-64
Trial Locations
- Locations (164)
Dothan Surgery Center
🇺🇸Dothan, Alabama, United States
Investigational Drug Services
🇺🇸Philadelphia, Pennsylvania, United States
Flowers Hospital
🇺🇸Dothan, Alabama, United States
Grant Medical Foundation, Ruby Hall Clinic
🇮🇳Pune, Maharashtra, India
Brigham and Women's Hospital - Office
🇺🇸Boston, Massachusetts, United States
Brigham and Women's Hospital
🇺🇸Boston, Massachusetts, United States
Valley View Surgery Center
🇺🇸Las Vegas, Nevada, United States
Sierra Clinical Research
🇺🇸Las Vegas, Nevada, United States
PrimeCare Medical Group
🇺🇸Houston, Texas, United States
Digestive Health Specialists
🇺🇸Dothan, Alabama, United States
KLIMED Marek Klimkiewicz
🇵🇱Bialystok, Poland
Endoscopy Center of Connecticut, LLC
🇺🇸Hamden, Connecticut, United States
Tower Radiology Center
🇺🇸Oldsmar, Florida, United States
Trident Care
🇺🇸Clearwater, Florida, United States
Brigham & Women's Hospital
🇺🇸Boston, Massachusetts, United States
The University of Chicago Medical Center (clinic address)
🇺🇸Chicago, Illinois, United States
Weill Cornell Medical College - New York Presbyterian Hospital
🇺🇸New York, New York, United States
University of Iowa Hospitals and Clinics
🇺🇸Iowa City, Iowa, United States
Policlinico Universitario Campus Bio-Medico di Roma
🇮🇹Roma, RM, Italy
Pyatigorsk City Clinical Hospital
🇷🇺Pyatigorsk, Stavropol Region, Russian Federation
Private Healthcare Institution "Clinical Hospital" Russian Railways-Medicine "Samara city"
🇷🇺Samara, Russian Federation
Karla Adriana Espinosa Bautista
🇲🇽Ciudad de Mexico, Mexico
MZ Badania Slowik Zymla Sp. j.
🇵🇱Knurow, Poland
Keio University Hospital
🇯🇵Shinjuku-ku, Tokyo, Japan
Kurume University Hospital
🇯🇵Kurume, Fukuoka, Japan
SBHI YaR "Regional Clinical Hospital"
🇷🇺Yaroslavl, Russian Federation
Indywidualna Specjalistyczna Praktyka Lekarska Maciej Zymla
🇵🇱Knurow, Poland
Spitalul Clinic Colentina
🇷🇴Bucuresti, Romania
Klinicki Centar Kragujevac
🇷🇸Kragujevac, Serbia
Clinical Hospital named after S.R. Mirotvortsev
🇷🇺Saratov, Russian Federation
Limited Liability Company "Medicinsky Center SibNovoMed"
🇷🇺Novosibirsk, Russian Federation
LLC Novosibirskiy Gastrocenter
🇷🇺Novosibirsk, Russian Federation
Sapporo Medical University Hospital
🇯🇵Sapporo, Hokkaido, Japan
National Hospital Organization Sendai Medical Center
🇯🇵Sendai, Miyagi, Japan
Fukuoka University Hospital
🇯🇵Fukuoka, Japan
ENDOSKOPIA Sp. z o. o.
🇵🇱Sopot, Poland
Municipal non-profit enterprise "City clinical hospital #2 named after O.O.Shalimov"
🇺🇦Kharkiv, Ukraine
Istanbul Universitesi Istanbul Tip Fakultesi
🇹🇷Istanbul, Turkey
Azienda Ospedaliera di Padova - U.O.C. di Gastroenterologia
🇮🇹Padova, Italy
Clinic of OSMU
🇷🇺Omsk, Russian Federation
MeDiNova Northamptonshire Quality Research Site
🇬🇧Corby, United Kingdom
BRCR Global Mexico
🇲🇽Guadalajara, Jalisco, Mexico
KDC "Evromedservis", OJSC
🇷🇺Moscow, Russian Federation
Tokyo Medical And Dental University Hospital
🇯🇵Bunkyo-ku, Tokyo, Japan
Centro Multidisciplinario para el Desarrollo Especializado de la Investigacion
🇲🇽Merida, Yucatan, Mexico
Smiq S. de R.L. de C.V.
🇲🇽Queretaro, Mexico
Municipal Non-profit Enterprise "Kyiv City Clinical Hospital #1"
🇺🇦Kyiv, Ukraine
Kocaeli Universitesi Tip Fakultesi, Ic Hastaliklari Anabilim Dali
🇹🇷Kocaeli, Turkey
Lenasia Clinical Trial Centre
🇿🇦Johannesburg, Gauteng, South Africa
Songklanagarind Hospital, Prince of Songkla University
🇹🇭Hat Yai, Songkhla, Thailand
Mersin Universitesi Tip Fakultesi Hastanesi
🇹🇷Mersin, Turkey
Universitas Private Hospital
🇿🇦Bloemfontein, FREE State, South Africa
Mediclinic Kloof Hospital
🇿🇦Pretoria, Gauteng, South Africa
Gastro LM s.r.o
🇸🇰Presov, Slovakia
Endoscopy Facility - Spire Little Aston Hospital
🇬🇧Sutton Coldfield, Birmingham, United Kingdom
Municipal non-profit enterprise of Kharkiv regional council "Regional clinical hospital"
🇺🇦Kharkiv, Ukraine
Dr van Dyk & Partners Inc
🇿🇦Bloemfontein, FREE State, South Africa
Medical Centre Medical Clinic Blagomed LLC
🇺🇦Kyiv, Ukraine
Hospital Universitario de Fuenlabrada
🇪🇸Fuenlabrada, Madrid, Spain
Arwyp Medical Centre
🇿🇦Kempton Park, Gauteng, South Africa
Municipal non-profit enterprise of Kyiv regional council "Kyiv regional clinical hospital"
🇺🇦Kyiv, Ukraine
Medical center of Limited Liability Company "Health Clinic", medical clinical research center
🇺🇦Vinnytsia, Ukraine
Bulent Ecevit Universitesi Tip Fakultesi
🇹🇷Zonguldak, Turkey
Spire Nottingham Hospital
🇬🇧Nottingham, United Kingdom
Endoscopy Facility - Orpington Endoscopy Centre
🇬🇧Orpington, United Kingdom
Emmed Research
🇿🇦Pretoria, Gauteng, South Africa
Radiology24 Jakaranda Hospital
🇿🇦Pretoria, Gauteng, South Africa
Clinresco Centres (Pty) Ltd
🇿🇦Kempton Park, Gauteng, South Africa
UO Malattie retto-Intestinali Ospedale "Sacro Cuore-don Calabria"
🇮🇹Negrar, Verona, Italy
King Chulalongkorn Memorial Hospital, Faculty of Medicine, Chulalongkorn University
🇹🇭Pathum Wan, Bangkok, Thailand
S.R. Kalla Memorial Gastro & General Hospital
🇮🇳Jaipur, Rajasthan, India
S.M.S. Medical College & Hospital
🇮🇳Jaipur, Rajasthan, India
Vanderbilt GI Endoscopy Lab at One Hundred Oaks
🇺🇸Nashville, Tennessee, United States
Vanderbilt Heart One Hundred Oaks
🇺🇸Nashville, Tennessee, United States
Vanderbilt Inflammatory Bowel Disease Clinic
🇺🇸Nashville, Tennessee, United States
Vanderbilt Laboratory Services North One Hundred Oaks
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center
🇺🇸Nashville, Tennessee, United States
VIP Trials
🇺🇸San Antonio, Texas, United States
Medlife S.A.
🇷🇴Bucuresti, Romania
Shree Giriraj Multispeciality Hospital
🇮🇳Rajkot, Gujarat, India
Asociacion IPS Medicos Internistas de Caldas
🇨🇴Manizales, Caldas, Colombia
Weill Cornell Medical College
🇺🇸New York, New York, United States
Magyar Imre Kórház
🇭🇺Ajka, Hungary
Clinexpert Tatabanya, Szent Borbala Hospital
🇭🇺Tatabanya, Hungary
Opsta Bolnica Subotica
🇷🇸Subotica, Serbia
"ACIBADEM City Clinic Diagnostic-Consultative Center" EOOD
🇧🇬Sofia, Bulgaria
DRC Gyogyszervizsgalo Kozpont Kft.
🇭🇺Balatonfured, Veszprem, Hungary
Twoja Przychodnia - Szczecinskie Centrum Medyczne
🇵🇱Szczecin, Poland
WIP Warsaw IBD Point Profesor Kierkus
🇵🇱Warszawa, Poland
NZOZ Vivamed Jadwiga Miecz
🇵🇱Warszawa, Poland
Centrum Medyczne Melita Medical
🇵🇱Wroclaw, Poland
Opsta Bolnica "Djordje Joanovic", Odeljenje Interno, Odsek Gastroenterologija
🇷🇸Zrenjanin, Serbia
ENDOMED, s.r.o.
🇸🇰Vranov nad Toplou, Slovakia
IATROS International
🇿🇦Bloemfontein, FREE State, South Africa
Phramongkutklao Hospital
🇹🇭Bangkok, Thailand
Aichi Medical University Hospital
🇯🇵Nagakute, Aichi, Japan
Toho University Sakura Medical Center
🇯🇵Sakura, Chiba, Japan
Egin Research Ltd
🇬🇧High Wycombe, United Kingdom
Research Institute of Antimicrobial Chemotherapy
🇷🇺Smolensk, Russian Federation
Tomsk Regional Clinical Hospital
🇷🇺Tomsk, Russian Federation
City Hospital JSC "Medical centre"
🇷🇺Tyumen, Russian Federation
Akumin
🇺🇸Tampa, Florida, United States
Tampa Bay Endoscopy Center
🇺🇸Tampa, Florida, United States
Alliance Clinical Research of Tampa
🇺🇸Tampa, Florida, United States
Lynn Institute of the Ozarks
🇺🇸Little Rock, Arkansas, United States
Surinder Saini, M.D., Inc.
🇺🇸Newport Beach, California, United States
Medical Research Center Of Connecticut, LLC
🇺🇸Hamden, Connecticut, United States
PACT Gastroenterology Center
🇺🇸Hamden, Connecticut, United States
Whitney Imaging
🇺🇸Hamden, Connecticut, United States
Medycal Research Inc.
🇺🇸Brooksville, Florida, United States
Safety Harbor Surgery
🇺🇸Clearwater, Florida, United States
Gastroenterology Consultants P.C.
🇺🇸Roswell, Georgia, United States
The University of Chicago Medical Center
🇺🇸Chicago, Illinois, United States
Michigan Endoscopy Center
🇺🇸Farmington Hills, Michigan, United States
New York Presbyterian Hospital - Weill Cornell Medical Center
🇺🇸New York, New York, United States
Weill Cornell Medical College- New York Presbyterian Hospital
🇺🇸New York, New York, United States
Perelman Center for Advanced Medicine
🇺🇸Philadelphia, Pennsylvania, United States
Gastroenterology Associates, PA of Greenville
🇺🇸Greenville, South Carolina, United States
Vanderbilt University Medical Center - GI Research Office
🇺🇸Nashville, Tennessee, United States
Vanderbilt One Hundred Oaks Imaging
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Med. Center
🇺🇸Nashville, Tennessee, United States
Vanderbilt University Medical Center- Heart Station (ECG)
🇺🇸Nashville, Tennessee, United States
Gastroenterology Consultants of San Antonio, PA
🇺🇸San Antonio, Texas, United States
South Texas Radiology Imaging Centers
🇺🇸San Antonio, Texas, United States
Gastroenterology Associates of Northern Virginia
🇺🇸Fairfax, Virginia, United States
Verity Research, Inc.
🇺🇸Fairfax, Virginia, United States
Medical Diagnostic Imaging
🇺🇸Wauwatosa, Wisconsin, United States
GI Associates
🇺🇸Wauwatosa, Wisconsin, United States
Concord Repatriation General Hospital
🇦🇺Concord, New South Wales, Australia
Mater Misericordiae Ltd.
🇦🇺South Brisbane, Queensland, Australia
Centre Hospitalier Regional Universitaire (CHU) de Lille - Hopital Claude Huriez
🇫🇷Lille Cedex, France
Centre Hospitalier Regional Universitaire (CHU) de Lille - CIC
🇫🇷Lille Cedex, France
CHU d'Amiens-Picardie - SITE SUD
🇫🇷Amiens Cedex 1, France
Centre Hospitalier Regional Universitaire (CHU) de Lille
🇫🇷Lille Cedex, France
CHU Hôtel-Dieu
🇫🇷Nantes Cedex 1, France
Centre Hospitalier Lyon Sud
🇫🇷Pierre-Benite Cedex, France
Centre Hospitalier Universitaire de Lyon Sud
🇫🇷Pierre-Bénite Cedex, France
Studiengesellschaft BSF UG (haftungsbeschränkt)
🇩🇪Halle/Saale, Germany
Deutsches Rotes Kreuz Schwesternschaft Berlin Gemeinnützige Krankenhaus GmbH
🇩🇪Berlin, Germany
Studiengesellschaft BSF Unternehmergesellschaft
🇩🇪Halle (Saale), Germany
Clinfan Kft.
🇭🇺Szekszard, Hungary
Clinexpert Egészségügyi Szolgáltató és Kereskedelmi Kft.
🇭🇺Budapest, Hungary
Life Egészségcentrum
🇭🇺Székesfehérvár, Hungary
Deák Jenő Kórház
🇭🇺Tapolca, Hungary
Szofia Private Clinic
🇭🇺Veszprém, Hungary
Gujarat Hospital Gastro and Vascular Centre, Opp. Shree Ram Petrol Pump
🇮🇳Surat, Gujarat, India
Surat Institute of Digestive Sciences
🇮🇳Surat, Gujarat, India
M.S. Ramaiah Medical College and Hospitals,
🇮🇳Bangalore,, Karnataka, India
M.S. Ramaiah Medical College and Hospitals
🇮🇳Bangalore, Karnataka, India
A.O.U. dell'Università degli Studi della Campania "Luigi Vanvitelli"
🇮🇹Napoli, Naples, Italy
IRCCS "Saverio de Bellis", UOC Gastroenterologia
🇮🇹Castellana Grotte, Bari, Italy
Istituto Clinico Humanitas Centro per le Malattie Infiammatorie Croniche dell'Intestino - IBD Cent
🇮🇹Rozzano, Milan, Italy
Perm Clinical Centre of the Federal Medical-Biological Agency
🇷🇺Perm, Russian Federation
KM Management spol. s.r.o.
🇸🇰Nitra, Slovakia
Ahmed Kathrada Private Hospital
🇿🇦Johannesburg, Gauteng, South Africa
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi
🇹🇷Istanbul, Turkey
Medical Centre "DIACENTER" LLC
🇺🇦Zaporizhzhia, Ukraine
MeDiNova North London Quality Research Site
🇬🇧Northwood, Middlesex, United Kingdom
Chest X-ray Facility - BMI Bishops Wood Hospital
🇬🇧Northwood, United Kingdom
Allegiance Internal Medicine and Allegiance Research Specialists
🇺🇸Wauwatosa, Wisconsin, United States
Gastroenterology Associates of Northern VA
🇺🇸Fairfax, Virginia, United States
Royal Adelaide Hospital
🇦🇺Adelaide, South Australia, Australia
University Hospitals Leuven/Department of Gastroenterology
🇧🇪Leuven, Belgium
Municipal Non-profit enterprise of Kyiv Regional Council "Kyiv regional hospital"
🇺🇦Kyiv, Ukraine